Abstract
Psoriasis is now recognized as the most prevalent T-cell-mediated inflammatory disease in humans. While there are a wide variety of therapies that are indicated for the management of psoriasis with different modes of action and different effects, currently, psoriasis is considered as an incurable disease. Biological agents interfere with specific components of the autoimmune response and offer a new therapeutic approach to psoriasis. Efalizumab is a recombinant, humanized immunoglobulin G1 anti-CD11a monoclonal antibody that has been developed for the potential treatment of plaque psoriasis. It has been demonstrated in Phase III clinical trials to have a rapid onset of clinical response and to control chronic moderate-to-severe plaque psoriasis over 1 year of treatment. It has also been reported to have a positive impact on patient quality of life.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
